VDR and chronic kidney disease: Normal strategies for the treatment of CKD have emerged over the past years, such as endothelin antagonists, vitamin D receptor agonists, anti-inflammatory agents, bardoxolone, pentoxifylline, etc. Despite promising results in experimental models and small randomized studies, adequately powered randomized trials are required to evaluate the benefits and risks of these therapies in the CKD population (Lambers Heerspink and De Zeeuw, 2013; Pena-Polanco and Fried, 2016).